BMS-P5 is a potent, specific inhibitor of peptidylarginine deiminase 4 (PAD4) with IC50 of 98 nM.
BMS-P5 is selective for PAD4 over PAD1, -2, and -3 (IC50s >10 uM).
BMS-P5 inhibits PAD4 and prevents mouse myeloma-induced NET formation, prevents NETosis induced by human myeloma cells.
BMS-P5 significantly reduces plasma levels of cell-free DNA, exhibits anti-tumor effect in a syngeneic mouse model of multiple myeloma.
